NEW YORK, June 27, 2023 — NASHNET, a Kinetix Group network of excellence dedicated to advancing care pathways for nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), announced the release of an innovative white paper. The paper is titled Biomarkers for Diagnosing and Staging Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Current Perspectives and Potential Future Applications.
Tag: NASHNET
NASHNET Biomarkers White Paper
In support of the Global Liver Institute campaign for International NASH Day, NASHNET developed a groundbreaking white paper titled “Biomarkers for Diagnosing and Staging Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH): Current Perspectives and Potential Future Applications.” The white paper sheds light on guideline-directed and optimal use of biomarkers to diagnose or stage NASH. Special thanks… Continue reading NASHNET Biomarkers White Paper
NASHNET Designates Eighth Center of Excellence for Nonalcoholic Steatohepatitis
NEW YORK, January 9, 2020 – Eight leading care delivery systems from across the country have been designated as founding charter members of NASHNET and Centers of Excellence (COEs).
PM360 Announces NASHNET, pioneered by The Kinetix Group, as a Finalist for Its 2019 Trailblazer Award
NEW YORK, August 27, 2019 – NASHNET has been selected as a finalist in the 11th annual PM360 Trailblazer Awards within the Product/Service Launch category. NASHNET is a unique, care delivery model for the treatment of non-alcoholic fatty liver disease (NAFLD) that was founded and launched in 2018 by The Kinetix Group (TKG). TKG has been chosen alongside reputable marketing firms and industry powerhouses for this award.
Univision Joins NASHNET in Advancing Awareness of NASH in Latino Populations
NEW YORK, June 11, 2019 – NASH Network (NASHNET), a global Centers of Excellence Network represented by leading healthcare systems in collaboration with The Kinetix Group, is committed to non-alcoholic steatohepatitis (NASH) care delivery innovation with a mission to create a standard of care for NASH, a high-volume chronic condition.
NASHNET Expands Into the European Union
NEW YORK, May 16, 2019 – NASHNET, powered by The Kinetix Group, has focused its efforts on expanding its reach to the European Union. NAFLD/NASH is an international issue, affecting nearly 1 billion people around the world.1
The Kinetix Group and Consulting at McCann Health’s Research Report on Quality Measures for Nonalcoholic Steatohepatitis (NASH) to Be Presented at ISPOR 2019
NEW YORK, March 26, 2019 – The Kinetix Group, in partnership with Consulting at McCann Health, has authored a research report that has been accepted to be exhibited as a poster presentation at ISPOR 2019 in New Orleans on May 20, 2019. The report is titled, “Which Outcome & Quality Measures Do Leading KOLs Who Treat Nonalcoholic Steatohepatitis (NASH) Recommend flor Value-Based Contracting Across Multiple Stakeholders?”, and analyzes primary and secondary research, including insights gathered from 12 US key opinion leaders (KOLs).
The Kinetix Group Partners with Rimidi to Launch a Clinical Care Partnership for the Management of Nonalcoholic Steatohepatitis (NASH)
NEW YORK, August 30, 2018 – The Kinetix Group in partnership with Rimidi, an Atlanta-based health care technology firm, announced a partnership focused on improving Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) care delivery leveraging NASHNET, a global centers of excellence network.
The Nonalcoholic Steatohepatitis (NASH) Network in Collaboration with Echosens Launches a Real World Evidence Model
NEW YORK, August 23, 2018 – The global NASH market is projected to reach $21.5 billion by 2025, with NASH being the leading cause of liver transplantation in the US in the coming years. 1 The NASH Network (NASHNET), in collaboration with The Kinetix Group, has launched a Real World Evidence study to optimize care delivery for patients with Non-Alcoholic Steatohepatitis (NASH). This initiative is in partnership with Echosens, the innovators and marketers of the FibroScan® family of products.
The Nonalcoholic Steatohepatitis (NASH) Network in Collaboration with The Kinetix Group Participates in the International Liver Congress 2018
NEW YORK, April 6, 2018 – The NASH Network (NASHNET), in collaboration with The Kinetix Group is focused on improving NASH care delivery by collaboration on innovation, best practice sharing, and real world research. NASHNET will be participating at the upcoming International Liver Congress, hosted by the European Association for the Study of the Liver (EASL) on April 11th – 15th at Paris Expo Porte de Versailles in Paris, France.